ID CMB HC.PH.BIO.CMB
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| X4 Pharmaceuticals, Inc | XFOR | United States of America | $385.50M | 848 |
| SIGA TECHNOLOGIES INC | SIGA | United States of America | $311.28M | 1,087 |
| Akebia Therapeutics, Inc. | AKBA | United States of America | $250.90M | 929 |
| Autolus Therapeutics plc | AUTL | United Kingdom | $367.28M | 404 |
| Hansa Biopharma | HNSA | Sweden | $364.60M | 667 |
| PUMA BIOTECHNOLOGY, INC. | PBYI | United States of America | $343.93M | 1,137 |
| DELCATH SYSTEMS, INC. | DCTH | United States of America | $434.63M | 1,562 |
| AMARIN CORP PLC\UK | AMRN | United States of America | $297.76M | 1,502 |
| scPharmaceuticals Inc. Delisted | SCPH | United States of America | $304.36M | 439 |
| LENZ Therapeutics, Inc. | LENZ | United States of America | $286.89M | 381 |
| Evolus, Inc. | EOLS | United States of America | $256.34M | 633 |
| Coherus Oncology, Inc. | CHRS | United States of America | $232.15M | 983 |
| Genfit S.A. | GNFT | United States of America | $244.43M | 210 |
| Egetis Therapeutics | EGTX | Sweden | $268.69M | 339 |
| Gongwin Biopharm Holdings Co., Ltd. | 6617 | Taiwan | $272.96M | 885 |
| Arcturus Therapeutics Holdings Inc. | ARCT | United States of America | $214.03M | 462 |
| MediWound Ltd. | MDWD | Israel | $215.94M | 426 |
| FENNEC PHARMACEUTICALS INC. | FENC | Canada | $212.02M | 867 |
| TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED | 4157 | Taiwan | $202.64M | 1,655 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | United States of America | $199.74M | 1,499 |
| Santhera Pharmaceuticals Holding AG | SANN | Switzerland | $180.36M | 76 |
| Protalix BioTherapeutics, Inc. | PLX | United States of America | $168.39M | 2,450 |
| Oncopeptides | ONCO | Sweden | $163.23M | 639 |
| Theratechnologies Inc. Delisted | THTX | Canada | $155.87M | 308 |
| Humacyte, Inc. | HUMA | United States of America | $232.01M | 539 |
| HERON THERAPEUTICS, INC. | HRTX | United States of America | $140.63M | 1,453 |
| Karyopharm Therapeutics Inc. | KPTI | United States of America | $205.78M | 1,242 |
| Alpha Cognition Inc. | ACOG | Canada | $132.39M | 225 |
| SHIELD THERAPEUTICS PLC | STX | United Kingdom | $91.33M | 442 |
| Sol-Gel Technologies Ltd. | SLGL | Israel | $99.10M | 329 |
| Seres Therapeutics, Inc. | MCRB | United States of America | $86.28M | 746 |
| ECO ANIMAL HEALTH GROUP PLC | EAH | United Kingdom | $85.48M | 454 |
| Verrica Pharmaceuticals Inc. | VRCA | United States of America | $105.13M | 562 |
| Orexo | ORX | Sweden | $72.85M | 975 |
| PhytoHealth Corporation | 4108 | Taiwan | $74.40M | 2,238 |
| IMMUCELL CORP | ICCC | United States of America | $87.75M | 840 |
| CITIUS ONCOLOGY, INC. | CTOR | United States of America | $72.53M | 248 |
| Scilex Holding Co | SCLX | United States of America | $66.67M | 713 |
| Moberg Pharma | MOB | Sweden | $45.27M | 886 |
| RELIEF Therapeutics Holding AG | RLF | Switzerland | $46.09M | 412 |
| Zhengye Biotechnology Holding Ltd | ZYBT | United States of America | $40.07M | 61 |
| Atara Biotherapeutics, Inc. | ATRA | United States of America | $89.38M | 1,176 |
| KYNTRA BIO, INC. | KYNB | United States of America | $39.28M | 1,205 |
| Intervacc AB | IVACC | Sweden | $45.59M | 407 |
| Marinomed Biotech AG | MARI | Austria | $25.44M | 525 |
| BioXcel Therapeutics, Inc. | BTAI | United States of America | $34.12M | 738 |
| AYTU BIOPHARMA, INC | AYTU | United States of America | $23.51M | 952 |
| LakeShore Biopharma Co., Ltd. | LSB | United States of America | $25.84M | 151 |
| Advicenne | ALDVI | France | $30.40M | 313 |
| Outlook Therapeutics, Inc. | OTLK | United States of America | $118.10M | 845 |
Other names for this activity, and where neighboring activities go instead.
No aliases listed.
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Also preclinical, drug developer
https://financialfilings.com/oics/CMB/
This page is keyed by the class ID CMB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.